Skip to content
ALS News Today logo Newsletter
Newsletter
  • About ALS
    What is ALS?
    Causes and risk factors
    Diagnosis
    Symptoms
    • Speech problems
    • Breathing and swallowing
    • Pseudobulbar affect
    Types of ALS
    • Familial ALS
    • Sporadic ALS
    Living with ALS
    • Mental health
    • Diet
    • Exercise
    • Aids and adaptations
  • Treatments
    Approved treatments
    Experimental treatments
    Non-drug treatments
  • News
  • Columns
    Joyful Sorrow — Kristin Neva
    Living Well With ALS — Dagmar Munn
    Thunder Road — Juliet Taylor
    Archived columns
    • OutSpoken — James Clingman
    • The Mighty Mind — Rachel Doboga
    In memoriam
    • Notes From the ALS Front — Rick Jobus
  • Forums
  • Advocacy partners
  • What can we help you find today?

December 9, 2024 News by Esteban Dominguez Cerezo, MS

First ALS patient dosed in Phase 1 trial testing Quralis’ QRL-101

Quralis has dosed the first patient in a Phase 1 clinical trial testing QRL-101 — its treatment candidate for reducing nerve cell overactivation in amyotrophic lateral sclerosis (ALS) and thus potentially slowing disease progression — in adults with ALS. The proof-of-mechanism QRL-101-04 trial (NCT06714396) is still enrolling…

October 21, 2024 News by Margarida Maia, PhD

First SOD1-ALS patient dosed in trial of AMT-162 gene therapy

The first patient has been dosed in a Phase 1/2 clinical trial of AMT-162, the one-time gene therapy in development by uniQure for treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, when the condition is thus known as SOD1-ALS. The open-label EPISOD1 clinical…

August 9, 2017 News by Margarida Azevedo, MSc

Amylyx Pharmaceuticals Doses First Patient in Phase 2 Trial of AMX0035 as an ALS Therapy

Amylyx Pharmaceuticals has dosed the first patient in a Phase 2 clinical trial that will assess AMX0035’s ability to treat amyotrophic lateral sclerosis. Researchers are seeking 132 participants for the CENTAUR study (NCT03127514). A unique feature of the trial is that Amylyx designed it in collaboration with patients and caregivers…

Recent Posts

  • Prioritizing comfort as we continue settling in for the ride with ALS
  • Clene working with FDA on accelerated approval for CNM-Au8
  • An author discusses ALS and how she became an activist
  • Longitude Prize on ALS encourages use of AI to find new treatments
  • Living near toxic algal blooms tied to shorter survival in ALS patients


Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.